Rein Financial Statements From 2010 to 2025

RNTX Stock   1.14  0.10  8.06%   
Rein Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Rein Therapeutics' valuation are provided below:
Market Capitalization
32.6 M
Earnings Share
(2.94)
We have found one hundred ten available trending fundamental ratios for Rein Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Rein Therapeutics recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 39.2 K in 2025. Enterprise Value is likely to rise to about (12.2 M) in 2025
Check Rein Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rein Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 66.2 K, Selling General Administrative of 14.6 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.0E-4. Rein financial statements analysis is a perfect complement when working with Rein Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Rein Stock
Check out the analysis of Rein Therapeutics Correlation against competitors.
For more information on how to buy Rein Stock please use our How to Invest in Rein Therapeutics guide.

Rein Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets43.9 M69.2 M29.6 M
Slightly volatile
Other Current Liabilities3.3 M4.8 M2.7 M
Slightly volatile
Total Current Liabilities4.9 M5.7 M3.9 M
Slightly volatile
Property Plant And Equipment Net9501000M
Very volatile
Accounts Payable1.1 M911 K1.1 M
Slightly volatile
Cash10.8 M12.9 MM
Slightly volatile
Non Current Assets Total58.4 M55.6 M14.4 M
Slightly volatile
Non Currrent Assets Other1.9 KK937.3 K
Slightly volatile
Cash And Short Term Investments18 M12.9 M16.4 M
Slightly volatile
Liabilities And Stockholders Equity43.9 M69.2 M29.6 M
Slightly volatile
Other Current Assets1.2 M792 K857.4 K
Slightly volatile
Other Stockholder Equity226.6 M360.7 M143.5 M
Slightly volatile
Total Liabilities14.1 M14.8 M56.4 M
Slightly volatile
Total Current Assets18.9 M13.7 M17.2 M
Slightly volatile
Common Stock66.4 K108 K40.9 K
Slightly volatile
Short and Long Term Debt Total41 K43.2 K3.4 M
Slightly volatile
Short Term Debt41 K43.2 K305.4 K
Slightly volatile
Long Term Debt175.2 K197.1 K214.9 K
Slightly volatile
Common Stock Shares Outstanding17 K17.9 K12 M
Slightly volatile
Net Invested Capital14.6 M9.4 M14.5 M
Pretty Stable
Property Plant And Equipment Gross393.2 K433.6 K254.2 K
Slightly volatile
Short and Long Term Debt134.4 K151.2 K164.8 K
Slightly volatile
Capital Stock93.5 K108 K59.9 K
Slightly volatile
Net Working Capital15.4 M7.9 M14.7 M
Pretty Stable
Intangible Assets51.1 M48.5 M75.5 M
Slightly volatile
Non Current Liabilities Other221.6 K249.3 K271.8 K
Slightly volatile

Rein Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization66.2 K63 K8.2 K
Slightly volatile
Selling General Administrative14.6 M13.9 M1.8 M
Slightly volatile
Other Operating Expenses68.4 M65.1 M8.4 M
Slightly volatile
Research Development15 M14.2 M1.8 M
Slightly volatile
Total Operating Expenses68.4 M65.1 M8.4 M
Slightly volatile
Reconciled Depreciation101.6 K63 K147.9 K
Slightly volatile
Net Interest Income403.3 K460 K322.7 K
Slightly volatile
Interest Income403.3 K460 K322.7 K
Slightly volatile
Selling And Marketing Expenses11.1 M12.5 M13.6 M
Slightly volatile
Cost Of Revenue50.4 K56.7 K61.8 K
Slightly volatile

Rein Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.9 M1.1 M1.4 M
Slightly volatile
Begin Period Cash Flow10.3 M17.3 M8.4 M
Slightly volatile
Depreciation59.9 K63 K211.2 K
Slightly volatile
End Period Cash Flow11 M12.9 M8.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio7.0E-48.0E-42.089
Slightly volatile
Book Value Per Share4.1 KK1.4 K
Slightly volatile
Capex To Depreciation1.421.492.0021
Pretty Stable
PB Ratio7.0E-48.0E-42.089
Slightly volatile
Payables Turnover0.05540.06220.0679
Slightly volatile
Cash Per Share6817171.3 K
Slightly volatile
Days Payables Outstanding4.2 K4.8 K5.2 K
Slightly volatile
Income Quality0.340.35450.8574
Slightly volatile
Intangibles To Total Assets0.870.78040.8091
Pretty Stable
Net Debt To EBITDA0.440.4587316
Very volatile
Current Ratio4.212.37554.0425
Slightly volatile
Shareholders Equity Per Share4.1 KK1.4 K
Slightly volatile
Debt To Equity0.00760.0080.1766
Slightly volatile
Capex Per Share33.4231.8210.7078
Slightly volatile
Interest Debt Per Share10.849.44.6675
Slightly volatile
Debt To Assets5.0E-45.0E-40.1129
Slightly volatile
Price Book Value Ratio7.0E-48.0E-42.089
Slightly volatile
Days Of Payables Outstanding4.2 K4.8 K5.2 K
Slightly volatile
Ebt Per Ebit1.090.98771.0232
Slightly volatile
Effective Tax Rate0.01920.02160.0236
Slightly volatile
Long Term Debt To Capitalization0.01420.01590.0174
Slightly volatile
Total Debt To Capitalization0.00760.0080.1391
Slightly volatile
Debt Equity Ratio0.00760.0080.1766
Slightly volatile
Quick Ratio4.212.37554.0425
Slightly volatile
Net Income Per E B T0.780.880.9593
Slightly volatile
Cash Ratio2.442.23782.0008
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.161.0335
Slightly volatile
Price To Book Ratio7.0E-48.0E-42.089
Slightly volatile
Debt Ratio5.0E-45.0E-40.1129
Slightly volatile
Price Fair Value7.0E-48.0E-42.089
Slightly volatile

Rein Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap39.2 K41.3 K25.4 M
Slightly volatile

Rein Fundamental Market Drivers

About Rein Therapeutics Financial Statements

Rein Therapeutics investors use historical fundamental indicators, such as Rein Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Rein Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue56.7 K50.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Rein Stock Analysis

When running Rein Therapeutics' price analysis, check to measure Rein Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rein Therapeutics is operating at the current time. Most of Rein Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rein Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rein Therapeutics' price. Additionally, you may evaluate how the addition of Rein Therapeutics to your portfolios can decrease your overall portfolio volatility.